LOS ANGELES- Optimi Health Corp, a Health Canada licensed GMP psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, has announced several significant milestones in its international psychedelic supply operations and corporate marketing strategy.
Optimi has successfully completed its first international shipment of in-house manufactured MDMA active pharmaceutical ingredient (API) to the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV) in Israel. This was facilitated by the necessary Export Permit from Health Canada, marking a pivotal step in Optimi’s mission to support global psychedelic research and innovation.
“Completing our first international export of MDMA to Israel is an important milestone for the company,” said Bill Ciprick, CEO of Optimi. “Now that we have our Drug Establishment Licence, this accomplishment highlights our capability to manufacture MDMA in-house for clients around the world and efficiently deliver the product to an international client. It also underscores our dedication to expanding the availability of high-quality, controlled substances for important scientific research and therapeutic applications worldwide.”
Export Authorization and Compliance
Optimi has also secured the Canadian Export Reporting System (CERS) and Canada Border Services Agency (CBSA) Exporters Authorization ID, which confirms its capacity to export controlled substances from Canada. This authorization is crucial for maintaining compliance with international trade regulations and ensuring smooth logistics for future shipments.
Investor Relations
Optimi has retained Oak Hill Financial Inc. to provide comprehensive investor relations, business, and capital markets advisory services at a rate of CDN$12,000 per month for an initial three-month term, continuing month to month at the company’s discretion. Oak Hill will assist Optimi in effectively communicating its latest corporate milestones to potential new investors and engaging with the investment community.
“We are excited to partner with Oak Hill to bolster our investor relations efforts,” added Jacob Safarik, Chief Financial Officer of Optimi. “Their expertise will be invaluable as we continue to expand our shareholder base and reach new milestones in the psychedelic pharmaceuticals industry.”
Recent Corporate Highlights
- Drug Establishment Licence: On June 3, 2024, Health Canada awarded Optimi a Drug Establishment Licence for the production and distribution of MDMA and psilocybin capsules and the fabrication of Active Pharmaceutical Ingredients (APIs) extracted from plant sources. Optimi is now recognized as a GMP-compliant pharmaceutical drug manufacturer.
- International Availability: Authorized psychiatrists in Australia can request the importation of Optimi’s MDMA and psilocybin capsules for use in patients. Available products include MDMA Capsules (40mg and 60mg) for PTSD and Psilocybin Capsules (5mg) for Treatment-Resistant Depression.
- Initial Order Fulfillment: Optimi was issued an import certificate to supply 160 doses of MDMA and psilocybin to fulfill patient prescriptions, facilitated by Mind Medicine Australia.
- Comprehensive GMP Solutions: Optimi now provides customers with GMP psychedelic drug solutions for commercialization, covering manufacturing, export, and distribution from their facility in Princeton, BC, Canada.
